{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:49:56Z","timestamp":1782478196945,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["ID 22759"],"award-info":[{"award-number":["ID 22759"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funding by Scientific Direction of IRCCS Regina Elena National Cancer Institute."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hyperthermic intraperitoneal administration of chemotherapy (HIPEC) increases local drug concentrations and reduces systemic side effects associated with prolonged adjuvant intraperitoneal exposure in patients affected by either peritoneal malignancies or metastatic diseases originating from gastric, colon, kidney, and ovarian primary tumors. Mechanistically, the anticancer effects of HIPEC have been poorly explored. Herein we documented that HIPEC treatment promoted miR-145-5p expression paired with a significant downregulation of its oncogenic target genes c-MYC, EGFR, OCT4, and MUC1 in a pilot cohort of patients with ovarian peritoneal metastatic lesions. RNA sequencing analyses of ovarian peritoneal metastatic nodules from HIPEC treated patients unveils HSF-1 as a transcriptional regulator factor of miR-145-5p expression. Notably, either depletion of HSF-1 expression or chemical inhibition of its transcriptional activity impaired miR-145-5p tumor suppressor activity and the response to cisplatin in ovarian cancer cell lines incubated at 42\u2009\u00b0C. In aggregate, our findings highlight a novel transcriptional network involving HSF-1, miR145-5p, MYC, EGFR, MUC1, and OCT4 whose proper activity contributes to HIPEC anticancer efficacy in the treatment of ovarian metastatic peritoneal lesions.<\/jats:p>","DOI":"10.1038\/s41419-023-06064-9","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:01:42Z","timestamp":1692450102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["HSF-1\/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-1125","authenticated-orcid":false,"given":"Silvia","family":"Di Agostino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-2895","authenticated-orcid":false,"given":"Sara","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-6962","authenticated-orcid":false,"given":"Claudio","family":"Pulito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ganci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1098-7705","authenticated-orcid":false,"given":"Fabio","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Goeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Scalera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2724-872X","authenticated-orcid":false,"given":"Francesca","family":"Rollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-9522","authenticated-orcid":false,"given":"Anna","family":"Bagnato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Diodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-7168","authenticated-orcid":false,"given":"Mariantonia","family":"Carosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Rufini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Giofr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Carboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Muti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-8605","authenticated-orcid":false,"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Strano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-2241","authenticated-orcid":false,"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"6064_CR1","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41416-022-01874-8","volume":"127","author":"RL Hollis","year":"2022","unstructured":"Hollis RL, Croy I, Churchman M, Bartos C, Rye T, Gourley C, et al. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. Br J Cancer. 2022;127:1034\u201342.","journal-title":"Br J Cancer"},{"key":"6064_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih IEM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186:733\u201347.","journal-title":"Am J Pathol"},{"key":"6064_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0590-x","volume":"10","author":"SYC Yang","year":"2018","unstructured":"Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, et al. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med. 2018;10:81.","journal-title":"Genome Med"},{"key":"6064_CR4","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1158\/0008-5472.CAN-11-3834","volume":"72","author":"L Szabova","year":"2012","unstructured":"Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 2012;72:4141\u201353.","journal-title":"Cancer Res"},{"key":"6064_CR5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"6064_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/cancers13030523","volume":"13","author":"F Carboni","year":"2021","unstructured":"Carboni F, Federici O, Sperduti I, Zazza S, Sergi D, Corona F, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from epithelial ovarian cancer: a 20-year single-center experience. Cancers. 2021;13:523.","journal-title":"Cancers"},{"key":"6064_CR7","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.3802\/jgo.2022.33.e54","volume":"33","author":"JH Kim","year":"2022","unstructured":"Kim JH, Lee DE, Lee Y, Ha HI, Chang YJ, Chang SJ, et al. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01). J Gynecol Oncol. 2022;33:e54.","journal-title":"J Gynecol Oncol"},{"key":"6064_CR8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:1363\u20134.","journal-title":"N Engl J Med"},{"key":"6064_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","volume":"47","author":"SN Koole","year":"2021","unstructured":"Koole SN, Kieffer JM, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur J Surg Oncol. 2021;47:101\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"6064_CR10","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1073\/pnas.0510565103","volume":"103","author":"S Volinia","year":"2006","unstructured":"Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103:2257\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6064_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","volume":"9","author":"R Garzon","year":"2010","unstructured":"Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9:775\u201389.","journal-title":"Nat Rev Drug Discov"},{"key":"6064_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1756-9966-31-38","volume":"31","author":"R Ma","year":"2012","unstructured":"Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012;31:38.","journal-title":"J Exp Clin Cancer Res"},{"key":"6064_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861\u201374.","journal-title":"Nat Rev Genet"},{"key":"6064_CR14","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.21037\/tcr-20-2530","volume":"10","author":"M Vahabi","year":"2021","unstructured":"Vahabi M, Blandino G, Di Agostino S. MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. Transl Cancer Res. 2021;10:3090\u2013110.","journal-title":"Transl Cancer Res"},{"key":"6064_CR15","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6064_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","volume":"8","author":"MA Cortez","year":"2011","unstructured":"Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"6064_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-374","volume":"9","author":"GM Arndt","year":"2009","unstructured":"Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009;9:374.","journal-title":"BMC Cancer"},{"key":"6064_CR18","doi-asserted-by":"publisher","first-page":"8699","DOI":"10.1158\/0008-5472.CAN-07-1936","volume":"67","author":"MV Iorio","year":"2007","unstructured":"Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699\u2013707.","journal-title":"Cancer Res"},{"key":"6064_CR19","first-page":"170","volume":"2","author":"M Sachdeva","year":"2010","unstructured":"Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res. 2010;2:170\u201380.","journal-title":"Am J Transl Res"},{"key":"6064_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1267-5","volume":"10","author":"T Bellissimo","year":"2019","unstructured":"Bellissimo T, Tito C, Ganci F, Sacconi A, Masciarelli S, Di Martino G, et al. Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells. Cell Death Dis. 2019;10:17.","journal-title":"Cell Death Dis"},{"key":"6064_CR21","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/cas.14517","volume":"111","author":"W Xu","year":"2020","unstructured":"Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W, et al. MiR-145 in cancer therapy resistance and sensitivity: a comprehensive review. Cancer Sci. 2020;111:3122\u201331.","journal-title":"Cancer Sci"},{"key":"6064_CR22","doi-asserted-by":"publisher","first-page":"35183","DOI":"10.18632\/oncotarget.5930","volume":"6","author":"S Donzelli","year":"2015","unstructured":"Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, et al. Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget. 2015;6:35183\u2013201.","journal-title":"Oncotarget"},{"key":"6064_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.canlet.2014.11.011","volume":"356","author":"TH Kim","year":"2015","unstructured":"Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, et al. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer Lett. 2015;356:937\u201345.","journal-title":"Cancer Lett"},{"key":"6064_CR24","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1073\/pnas.0808042106","volume":"106","author":"M Sachdeva","year":"2009","unstructured":"Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 2009;106:3207\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6064_CR25","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/bjc.2013.250","volume":"108","author":"M Avgeris","year":"2013","unstructured":"Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer. 2013;108:2573\u201381.","journal-title":"Br J Cancer"},{"key":"6064_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fcell.2020.00724","volume":"8","author":"W Wang","year":"2020","unstructured":"Wang W, Ding B, Lou W, Lin S. Promoter hypomethylation and miR-145-5p downregulation- mediated HDAC11 overexpression promotes sorafenib resistance and metastasis of hepatocellular carcinoma cells. Front Cell Dev Biol. 2020;8:724.","journal-title":"Front Cell Dev Biol"},{"key":"6064_CR27","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1055-9965.EPI-14-0398","volume":"23","author":"P Muti","year":"2014","unstructured":"Muti P, Sacconi A, Hossain A, Donzelli S, Ben Moshe NB, et al. Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study. Cancer Epidemiol Biomark Prev. 2014;23:2471\u201381.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"6064_CR28","doi-asserted-by":"publisher","first-page":"101042832096381","DOI":"10.1177\/1010428320963811","volume":"42","author":"AM Ibrahim","year":"2020","unstructured":"Ibrahim AM, Said MM, Hilal AM, Medhat AM, Abd, Elsalam IM. Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients. Tumour Biol. 2020;42:1010428320963811.","journal-title":"Tumour Biol"},{"key":"6064_CR29","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.2147\/CMAR.S320834","volume":"13","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Shi Y, Lyu T, Liu H, Shen L, Zhou T, et al. Identification and functional validation of differentially expressed microRNAs in ascites-derived ovarian cancer cells compared with primary tumour tissue. Cancer Manag Res. 2021;13:6585\u201397.","journal-title":"Cancer Manag Res"},{"key":"6064_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/PAS.0b013e31826cabbd","volume":"37","author":"K Garg","year":"2013","unstructured":"Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, et al. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian carcinomas. Am J Surg Pathol. 2013;37:138\u201346.","journal-title":"Am J Surg Pathol"},{"key":"6064_CR31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3389\/fonc.2020.01103","volume":"10","author":"UA Boyarskikh","year":"2020","unstructured":"Boyarskikh UA, Gulyaeva LF, Avdalyan AM, Kechin AA, Khrapov EA, Lazareva DG, et al. Spectrum of TP53 mutations in BRCA1\/2 associated high-grade serous ovarian cancer. Front Oncol. 2020;10:1103.","journal-title":"Front Oncol"},{"key":"6064_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23788-4","volume":"12","author":"R Duchnowska","year":"2022","unstructured":"Duchnowska R, Supernat AM, P\u0119ksa R, \u0141ukasiewicz M, Stokowy T, Ronen R, et al. Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases. Sci Rep. 2022;12:20537.","journal-title":"Sci Rep"},{"key":"6064_CR33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/CMAR.S191696","volume":"11","author":"D Ye","year":"2019","unstructured":"Ye D, Shen Z, Zhou S. Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manag Res. 2019;11:969\u201379.","journal-title":"Cancer Manag Res"},{"key":"6064_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biopha.2018.10.037","volume":"109","author":"T Zeinali","year":"2019","unstructured":"Zeinali T, Mansoori B, Mohammadi A, Baradaran B. Regulatory mechanisms of miR-145 expression and the importance of its function in cancer metastasis. Biomed Pharmacother. 2019;109:195\u2013207.","journal-title":"Biomed Pharmacother"},{"key":"6064_CR35","first-page":"5011","volume":"37","author":"A Sukovas","year":"2017","unstructured":"Sukovas A, Cesna V, Jasukaitiene A, Barauskas G, Nadisauskiene RJ, Dambrauskas Z, et al. Response of OVCAR-3 cells to cisplatin and hyperthermia: does hyperthermia really matter? Anticancer Res. 2017;37:5011\u20138.","journal-title":"Anticancer Res"},{"key":"6064_CR36","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/cells9081775","volume":"9","author":"RFCPA Helderman","year":"2020","unstructured":"Helderman RFCPA, L\u00f6ke DR, Verhoeff J, Rodermond HM, van Bochove GGW, Boon M, et al. The temperature-dependent effectiveness of platinum-based drugs mitomycin-C and 5-FU during hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer cell lines. Cells. 2020;9:1775.","journal-title":"Cells"},{"key":"6064_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-189","volume":"13","author":"KT Hua","year":"2014","unstructured":"Hua KT, Wang MY, Chen MW, Wei LH, Chen CK, Ko CH, et al. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer. 2014;13:189.","journal-title":"Mol Cancer"},{"key":"6064_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2135-2","volume":"16","author":"G Schmid","year":"2016","unstructured":"Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, et al. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer. 2016;16:102.","journal-title":"BMC Cancer"},{"key":"6064_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54401-w","volume":"9","author":"HD Reyes","year":"2019","unstructured":"Reyes HD, Devor EJ, Warrier A, Newtson AM, Mattson J, Wagner V, et al. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior. Sci Rep. 2019;9:17996.","journal-title":"Sci Rep"},{"key":"6064_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04508-2","volume":"17","author":"J Bi","year":"2022","unstructured":"Bi J, Zhang Y, Malmrose PK, Losh HA, Newtson AM, Devor EJ, et al. Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer. Cell Death Dis. 2022;17:59. 13","journal-title":"Cell Death Dis"},{"key":"6064_CR41","first-page":"3443","volume":"9","author":"L Wang","year":"2017","unstructured":"Wang L, Wu X, Wang B, Wang Q, Han L. Mechanisms of miR-145 regulating invasion and metastasis of ovarian carcinoma. Am J Transl Res. 2017;9:3443\u201351.","journal-title":"Am J Transl Res"},{"key":"6064_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7785\/tcrt.2012.500367","volume":"13","author":"W Zhang","year":"2014","unstructured":"Zhang W, Wang Q, Yu M, Wu N, Wang H. MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer. Technol Cancer Res Treat. 2014;13:161\u20138.","journal-title":"Technol Cancer Res Treat"},{"key":"6064_CR43","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/cancers13071648","volume":"13","author":"JB Loureiro","year":"2021","unstructured":"Loureiro JB, Raimundo L, Calheiros J, Carvalho C, Barcherini V, Lima NR, et al. Targeting p53 for melanoma treatment: counteracting tumour proliferation, dissemination and therapeutic resistance. Cancers. 2021;13:1648.","journal-title":"Cancers"},{"key":"6064_CR44","first-page":"3740","volume":"12","author":"Q Li","year":"2019","unstructured":"Li Q, Yu X, Yang L. MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt\/\u03b2-catenin pathway. Int J Clin Exp Pathol. 2019;12:3740\u201351.","journal-title":"Int J Clin Exp Pathol"},{"key":"6064_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11605-016-3222-z","volume":"21","author":"S Setua","year":"2017","unstructured":"Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, et al. Restitution of tumor suppressor MicroRNA-145 using magnetic nanoformulation for pancreatic cancer therapy. J Gastrointest Surg. 2017;21:94\u2013105.","journal-title":"J Gastrointest Surg"},{"key":"6064_CR46","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1166\/jbn.2020.2960","volume":"16","author":"J Zhai","year":"2020","unstructured":"Zhai J, Zhu Y, Liu J, An J, Yu Y, Li Y, et al. Enhanced suppression of disulfide cross-linking micelles nanocarriers loaded miR-145 delivering system via down-regulation of MYC and FSCN1 in colon cancer cells. J Biomed Nanotechnol. 2020;16:1183\u201395.","journal-title":"J Biomed Nanotechnol"},{"key":"6064_CR47","doi-asserted-by":"publisher","first-page":"101676","DOI":"10.1016\/j.suronc.2021.101676","volume":"40","author":"H Abdel Mageed","year":"2022","unstructured":"Abdel Mageed H, Van Der Speeten K, Sugarbaker P. The many faces of intraperitoneal chemotherapy. Surg Oncol. 2022;40:101676.","journal-title":"Surg Oncol"},{"key":"6064_CR48","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","volume":"167","author":"SI Kim","year":"2022","unstructured":"Kim SI, Kim JH, Lee S, Cho H, van Driel WJ, Sonke GS, et al. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis. Gynecol Oncol. 2022;167:547\u201356.","journal-title":"Gynecol Oncol"},{"key":"6064_CR49","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/cells9041046","volume":"9","author":"TL Prince","year":"2020","unstructured":"Prince TL, Lang BJ, Guerrero-Gimenez ME, Fernandez-Mu\u00f1oz JM, Ackerman A, Calderwood SK. HSF1: primary factor in molecular chaperone expression and a major contributor to cancer morbidity. Cells. 2020;9:1046.","journal-title":"Cells"},{"key":"6064_CR50","doi-asserted-by":"publisher","first-page":"188390","DOI":"10.1016\/j.bbcan.2020.188390","volume":"1874","author":"G Wang","year":"2020","unstructured":"Wang G, Cao P, Fan Y, Tan K. Emerging roles of HSF1 in cancer: cellular and molecular episodes. Biochim Biophys Acta Rev Cancer. 2020;1874:188390.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"6064_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/02656730701769841","volume":"24","author":"JL Roti Roti","year":"2008","unstructured":"Roti Roti JL. Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperth. 2008;24:3\u201315.","journal-title":"Int J Hyperth"},{"key":"6064_CR52","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.7150\/thno.22167","volume":"8","author":"S Di Agostino","year":"2018","unstructured":"Di Agostino S, Valenti F, Sacconi A, Fontemaggi G, Pallocca M, Pulito C, et al. Long Non-coding MIR205HG depletes Hsa-miR-590-3p leading to unrestrained proliferation in head and neck squamous cell carcinoma. Theranostics. 2018;8:1850\u201368.","journal-title":"Theranostics"},{"key":"6064_CR53","doi-asserted-by":"publisher","first-page":"188","DOI":"10.15252\/embr.201540488","volume":"2","author":"S Di Agostino","year":"2016","unstructured":"Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, et al. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016;2:188\u2013201.","journal-title":"EMBO Rep"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06064-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06064-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06064-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:04:56Z","timestamp":1692453896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06064-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["6064"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06064-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they agree to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"535"}}